Hansa Biopharma AB ( ($SE:HNSA) ) has provided an update. Hansa Biopharma announced that its Phase 3 trial for the treatment of anti-glomerular ...

The first partner company is on the path to market, but the implications are clear: eXoZymes has created a scalable production engine for molecules that were previously too rare or expensive to make.

An international research team has identified a human protein, ANKLE1, as the first DNA-cutting enzyme (nuclease) in mammals ...

For decades, Arieh Warshel, USC Distinguished Professor of Chemistry and a 2013 Nobel laureate, has used computer simulations ...

Researchers have captured the first detailed molecular snapshots of human polynucleotide phosphorylase (hPNPase) in action, ...

That’s the big idea behind Zymosense, “The Nanoassay Company,” a startup that’s spinning off technology developed in the lab ...

The curious minds at ColdFusion reveal how AI engineered an enzyme that eats plastic waste. How a US admiral decided to kill ...

Scott Nelson, left, and Nathaniel Kallmyer work in the laboratory of Zymosense, a startup company based in the Iowa State ...

By designing a squaric acid amide that binds a new site on ATP synthase, researchers created PRP020, a potential therapy for ...

Soil microbes remove carbon from the atmosphere and store it underground, revealing an overlooked pathway for storage in ...

Figure 1. ANKLE1 senses mechanical tension in DNA and helps resolve DNA bridges connecting separating daughter nuclei. ANKLE1 ...

Manufacture of multiple Dyadic-origin products by Fermbox Bio, enabling efficient production and market expansion of sustainable, animal-free proteins and enzymes. Dual-Sourcing flexibility, allowing ...